Literature DB >> 22621620

Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes.

Takeshi Hanagiri1, Yoshiki Shigematsu, Koji Kuroda, Tetsuro Baba, Hironobu Shiota, Yoshinobu Ichiki, Yoshika Nagata, Manabu Yasuda, Tomoko So, Mitsuhiro Takenoyama, Fumihiro Tanaka.   

Abstract

The difficulty in the induction and preparation of a large number of autologous tumor-specific cytotoxic T lymphocytes (CTL) from individual patients is one of major problems in their application to adoptive immunotherapy. The present study tried to establish the useful antitumor effectors by using γδ T cells through tumor-specific TCRαβ genes transduction, and evaluated the efficacy of their adoptive transfer in a non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice model. The TCRαβ gene was cloned from the HLA-B15-restricted CTL clone specific of the Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1). The cloned TCRαβ as well as the CD8 gene were transduced into γδ T cells induced from peripheral blood lymphocytes (PBL). Cytotoxic T lymphocyte activity was examined using a standard 4 h (51) Cr release assay. Mice with a xenotransplanted tumor were treated with an injection of effector cells. Successful transduction of TCRαβ was confirmed by the staining of KK-LC-1-specific tetramers. The γδ T cells transduced with TCRαβ and CD8 showed CTL activity against the KK-LC-1-positive lung cancer cell line in a HLA B15-restricted manner. Adoptive transfer of the effector cells in a mice model resulted in marked growth suppression of KK-LC-1- and HLA-B15-positive xenotransplanted tumors. Co-transducing TCRαβ and CD8 into γδ T cells yielded the same antigen-specific activity as an original CTL in vitro and in vivo. The TCRαβ gene transduction into γδ T cells is a promising strategy for developing new adoptive immunotherapy.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22621620      PMCID: PMC7659244          DOI: 10.1111/j.1349-7006.2012.02337.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  31 in total

Review 1.  Strategies for immunotherapy of cancer.

Authors:  C J Melief; R E Toes; J P Medema; S H van der Burg; F Ossendorp; R Offringa
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.

Authors:  V Kunzmann; E Bauer; J Feurle; F Weissinger; H P Tony; M Wilhelm
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

3.  Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung.

Authors:  Masakazu Sugaya; Mitsuhiro Takenoyama; Yoshiki Shigematsu; Tetsuro Baba; Takashi Fukuyama; Yoshika Nagata; Makiko Mizukami; Tetsuya So; Yoshinobu Ichiki; Manabu Yasuda; Tomoko So; Takeshi Hanagiri; Kenji Sugio; Kosei Yasumoto
Journal:  Int J Cancer       Date:  2007-03-01       Impact factor: 7.396

4.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.

Authors:  Marybeth S Hughes; Yik Y L Yu; Mark E Dudley; Zhili Zheng; Paul F Robbins; Yong Li; John Wunderlich; Robert G Hawley; Morvarid Moayeri; Steven A Rosenberg; Richard A Morgan
Journal:  Hum Gene Ther       Date:  2005-04       Impact factor: 5.695

Review 5.  Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.

Authors:  Håkan Mellstedt; Johan Vansteenkiste; Nick Thatcher
Journal:  Lung Cancer       Date:  2011-04-06       Impact factor: 5.705

6.  Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.

Authors:  Sachiko Okamoto; Junichi Mineno; Hiroaki Ikeda; Hiroshi Fujiwara; Masaki Yasukawa; Hiroshi Shiku; Ikunoshin Kato
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

7.  Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.

Authors:  Matilde Todaro; Matilde D'Asaro; Nadia Caccamo; Flora Iovino; Maria Giovanna Francipane; Serena Meraviglia; Valentina Orlando; Carmela La Mendola; Gaspare Gulotta; Alfredo Salerno; Francesco Dieli; Giorgio Stassi
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

8.  High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Authors:  Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

9.  Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients.

Authors:  Hideki Kimura; Toshihiko Iizasa; Aki Ishikawa; Masato Shingyouji; Mitsuru Yoshino; Masaki Kimura; Yutaka Inada; Keiko Matsubayashi
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

10.  Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

Authors:  Cyrille J Cohen; Yong F Li; Mona El-Gamil; Paul F Robbins; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

View more
  9 in total

Review 1.  T-cell-associated cellular immunotherapy for lung cancer.

Authors:  Ke Li; Qing Zhang; Yang Zhang; Jie Yang; Junnian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-08       Impact factor: 4.553

Review 2.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

Review 3.  Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer.

Authors:  Junying Wang; Xueju Wang
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

4.  Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.

Authors:  Jianxuan Zou; Dan Chen; Yunhui Zong; Sisi Ye; Jinle Tang; Huimin Meng; Gangli An; Xingding Zhang; Lin Yang
Journal:  Cancer Sci       Date:  2015-03-13       Impact factor: 6.716

5.  Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

6.  Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation.

Authors:  Jan Dörrie; Christian Krug; Christian Hofmann; Ina Müller; Verena Wellner; Ilka Knippertz; Stephan Schierer; Simone Thomas; Elke Zipperer; Dieter Printz; Gerhard Fritsch; Gerold Schuler; Niels Schaft; Rene Geyeregger
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

7.  Retraction.

Authors: 
Journal:  Cancer Sci       Date:  2014-01       Impact factor: 6.716

8.  Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Binghao Zhao; Wenxiong Zhang; Dongliang Yu; Jianjun Xu; Yiping Wei
Journal:  Oncotarget       Date:  2017-07-19

9.  Development of adoptive immunotherapy with KK-LC-1-specific TCR-transduced γδT cells against lung cancer cells.

Authors:  Yoshinobu Ichiki; Yoshiki Shigematsu; Tetsuro Baba; Hironobu Shiota; Takashi Fukuyama; Yoshika Nagata; Tetsuya So; Manabu Yasuda; Mitsuhiro Takenoyama; Kosei Yasumoto
Journal:  Cancer Sci       Date:  2020-09-16       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.